Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura

Key Points

• TMEM109 serves as a potential biomarker for relapse in thrombotic thrombocytopenic purpura, indicating disease progression.
• Results show a significant link between TMEM109 levels and relapse rates during patient follow-ups.
• Through proteomic profiling of bone marrow samples, relevant biomarkers were assessed for their predictive power.
• Findings may enable early detection and intervention strategies in thrombotic thrombocytopenic purpura, enhancing patient outcomes.